Cargando…
Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
Osteosarcoma (OS) is the most common form of primary bone tumor affecting mainly children and young adults. Despite therapeutic progress, the 5-year survival rate is 70%, but it drops drastically to 30% for poor responders to therapies or for patients with metastases. Identifying new therapeutic tar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067202/ https://www.ncbi.nlm.nih.gov/pubmed/33808130 http://dx.doi.org/10.3390/cells10040754 |
_version_ | 1783682747422736384 |
---|---|
author | Lallier, Morgane Marchandet, Louise Moukengue, Brice Charrier, Celine Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, François |
author_facet | Lallier, Morgane Marchandet, Louise Moukengue, Brice Charrier, Celine Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, François |
author_sort | Lallier, Morgane |
collection | PubMed |
description | Osteosarcoma (OS) is the most common form of primary bone tumor affecting mainly children and young adults. Despite therapeutic progress, the 5-year survival rate is 70%, but it drops drastically to 30% for poor responders to therapies or for patients with metastases. Identifying new therapeutic targets is thus essential. Heat Shock Proteins (HSPs) are the main effectors of Heat Shock Response (HSR), the expression of which is induced by stressors. HSPs are a large family of proteins involved in the folding and maturation of other proteins in order to maintain proteostasis. HSP overexpression is observed in many cancers, including breast, prostate, colorectal, lung, and ovarian, as well as OS. In this article we reviewed the significant role played by HSPs in molecular mechanisms leading to OS development and progression. HSPs are directly involved in OS cell proliferation, apoptosis inhibition, migration, and drug resistance. We focused on HSP27, HSP60, HSP70 and HSP90 and summarized their potential clinical uses in OS as either biomarkers for diagnosis or therapeutic targets. Finally, based on different types of cancer, we consider the advantage of targeting heat shock factor 1 (HSF1), the major transcriptional regulator of HSPs in OS. |
format | Online Article Text |
id | pubmed-8067202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80672022021-04-25 Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues Lallier, Morgane Marchandet, Louise Moukengue, Brice Charrier, Celine Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, François Cells Review Osteosarcoma (OS) is the most common form of primary bone tumor affecting mainly children and young adults. Despite therapeutic progress, the 5-year survival rate is 70%, but it drops drastically to 30% for poor responders to therapies or for patients with metastases. Identifying new therapeutic targets is thus essential. Heat Shock Proteins (HSPs) are the main effectors of Heat Shock Response (HSR), the expression of which is induced by stressors. HSPs are a large family of proteins involved in the folding and maturation of other proteins in order to maintain proteostasis. HSP overexpression is observed in many cancers, including breast, prostate, colorectal, lung, and ovarian, as well as OS. In this article we reviewed the significant role played by HSPs in molecular mechanisms leading to OS development and progression. HSPs are directly involved in OS cell proliferation, apoptosis inhibition, migration, and drug resistance. We focused on HSP27, HSP60, HSP70 and HSP90 and summarized their potential clinical uses in OS as either biomarkers for diagnosis or therapeutic targets. Finally, based on different types of cancer, we consider the advantage of targeting heat shock factor 1 (HSF1), the major transcriptional regulator of HSPs in OS. MDPI 2021-03-30 /pmc/articles/PMC8067202/ /pubmed/33808130 http://dx.doi.org/10.3390/cells10040754 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Lallier, Morgane Marchandet, Louise Moukengue, Brice Charrier, Celine Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, François Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues |
title | Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues |
title_full | Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues |
title_fullStr | Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues |
title_full_unstemmed | Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues |
title_short | Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues |
title_sort | molecular chaperones in osteosarcoma: diagnosis and therapeutic issues |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067202/ https://www.ncbi.nlm.nih.gov/pubmed/33808130 http://dx.doi.org/10.3390/cells10040754 |
work_keys_str_mv | AT lalliermorgane molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT marchandetlouise molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT moukenguebrice molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT charrierceline molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT baudhuinmarc molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT verrecchiafranck molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT orybenjamin molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues AT lamoureuxfrancois molecularchaperonesinosteosarcomadiagnosisandtherapeuticissues |